While the majority of immunotherapy development has targeted T cell-expressed negative regulators such as CTLA-4 and PD-1 (68, 69), few agents are currently under investigation, which are capable of modulating tolerogenic DCs in the tumor microenvironment. Here, CTLA4 is linked to neoplasm.